An eQMS selection is decided in a workshop and paid for over five years. The demonstration shows the modules working on the vendor's data, and the modules do work. What the demonstration cannot show you is how the system behaves after two years of your own change control, your own training records and your own deviations.
Veeva Quality, MasterControl, Greenlight Guru and Qualio are all credible, and they are aimed at different organisations. The useful comparison is not feature-by-feature — the feature lists converge — it is about fit, configuration burden, and what happens to validation each time the platform changes.
This is how we help clients compare, and then how we handle eQMS implementation implementation and validation whichever way the decision goes.
Where these platforms are genuinely aimed
Positioning matters more than features, because a platform built for a different size of company will fight you in ways no demonstration reveals.
Veeva Quality is cloud-native and sits in a wider Vault ecosystem covering regulatory and clinical. Its strongest case is an organisation that already runs, or intends to run, other Vault applications — the integration story is real and the data model is shared.
MasterControl is long-established with a broad quality suite and deep roots in manufacturing quality. Its strongest case is a company that wants wide module coverage from one vendor and has the appetite to configure it.
Greenlight Guru is built specifically around medical device quality and design control. For a device company that alignment is a genuine advantage; for a pharmaceutical manufacturer it is a mismatch.
Qualio targets smaller and earlier-stage life sciences companies, with implementation speed as the explicit proposition. Its strongest case is a company that needs a defensible quality system soon and does not have a quality IT function.
None of this is a ranking. A platform that is wrong for a 40-person biotech may be exactly right for a 4,000-person manufacturer.
The axis that actually predicts cost: configuration versus customisation
Ask one question and weight the answer heavily: how much of what you need is configuration of supplied functionality, and how much has to be built.
This determines the GAMP classification of your implementation, and therefore the validation depth, and therefore a large part of the five-year cost. Configured commercial functionality is category 4. Things written for you are category 5 and carry category 5 evidence. A platform that reaches your requirements through configuration will cost less to validate than one that reaches the same requirements through development, even if the licence is more expensive.
The trap is that this is invisible during selection. Vendors demonstrate configuration; the customisation emerges during design. The defence is to take your five most awkward requirements — not your most important, your most awkward — into the demonstration and ask specifically whether each is configuration or development. GAMP 5 Second Edition consulting is where we assess this properly before contracts are signed.
Modules you will actually use, and the ones you will not
Every eQMS covers document control, training, CAPA, change control, deviations, complaints and audit management. Suites are priced and sold as suites, and most organisations deploy a fraction.
Two of these carry disproportionate weight. Document control and training are where the system touches everybody in the company, every week — if they are awkward, adoption fails regardless of how good the rest is. CAPA and change control are where inspection findings concentrate, and where workflow rigidity does the most harm: a change control that cannot represent how your organisation actually makes decisions produces either workarounds outside the system or a queue.
Judge those two hardest, with your own process, in the demonstration. CAPA programme design is the practice where we see most of the remediation afterwards.
The integration surface
An eQMS is not an island. The connections that matter are to the systems that generate the events it manages: RIM for regulatory commitments, LIMS for laboratory deviations, MES for production events, ERP for materials and suppliers, and your HR system for the training records that underpin every signature.
The last one is routinely underestimated. If the eQMS does not know that someone's training has lapsed, it cannot stop them signing something they are not qualified to sign, and that is a control most organisations assume they have.
Ask how each integration is achieved, whether it is supported product functionality or a project to be built, and who owns it afterwards. Each built integration is category 5 scope and a long-term maintenance obligation.
What the move to cloud actually changes
All of these are delivered as cloud products, and that changes validation more than most selection processes account for. The vendor updates the platform on their schedule. Your validated state now has a dependency you do not control.
The questions to settle before signing, not after: how much notice is given before a production update, whether you can defer or stage it, whether there is a sandbox that receives the update first, what regression evidence the vendor provides, and what their qualification status is for the underlying infrastructure.
A vendor who updates production with little notice and no deferral is not disqualified by that — but it changes your approach from controlling change to monitoring it and responding, and that needs to be a documented decision rather than a discovery. cloud & SaaS validation and supplier qualification are where this gets handled.
AI features: what to ask now
Every eQMS now advertises AI. The useful question is not whether it has AI but whether the vendor has validated their own.
The draft EU GMP Annex 22, published for consultation in July 2025 and not yet in force, is a reasonable basis for the questions even though it carries no obligation today: what is the model approved for and what is it not, what evaluation gates each release, what safeguards sit on its outputs, how is drift monitored, and what happens to the workflow when the AI is unavailable.
A vendor who can answer those with documentation has thought about it. A vendor who answers with enthusiasm has not, and you will be the one explaining the gap. why human-in-the-loop can't be a footnote covers why the human review step is the part that has to be architectural rather than procedural.
Validating whichever you choose
The validation approach is similar across all four, and it is where the FDA's Computer Software Assurance guidance — finalised in September 2025 and reissued in February 2026 — changes the economics. Testing depth follows the risk each requirement carries.
In practice: scripted, boundary-focused testing on electronic signature, access control and segregation of duties, approval routing, training-gated actions, and audit trail completeness. Unscripted testing across the broad low-risk surface of search, navigation, dashboards and standard reports. Vendor evidence, assessed and documented, for standard platform behaviour the vendor tests and will show you.
Then keep the traceability live rather than rebuilding it at each periodic review, because a matrix maintained by hand reports whatever it was last told. eQMS implementation is the practice and book a demo if you want help running a selection or validating a decision already made.
A short decision checklist
- Which of our five most awkward requirements are configuration, and which are development?
- How does document control and training feel to a person who uses it twice a week?
- Can change control represent how we actually make decisions, without a workaround?
- Which integrations are supported product functionality and which are projects?
- Does the eQMS know when someone's training has lapsed, and can it stop them signing?
- How much notice before a production update, and can we defer it?
- If the platform uses AI, can the vendor document how it is governed and evaluated?
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.
